Prostatic Neoplasms
Showing 26 - 50 of 380
Prostatic Tumors Trial in Worldwide (Radium-223 dichloride (Xofigo, BAY88-8223), Matching (normal saline), Abiraterone)
Active, not recruiting
- Prostatic Neoplasms
- Radium-223 dichloride (Xofigo, BAY88-8223)
- +3 more
-
Anchorage, Alaska
- +163 more
Jan 18, 2023
Prostatic Tumors Trial in Worldwide (Apalutamide, Abiraterone acetate, Prednisone)
Active, not recruiting
- Prostatic Neoplasms
- Apalutamide
- +3 more
-
Phoenix, Arizona
- +183 more
Jan 17, 2023
Prostatic Tumors, Metastatic Castration-Resistant Prostate Cancer Trial in Worldwide (Abiraterone Acetate, Prednisone,
Active, not recruiting
- Prostatic Neoplasms
- Metastatic Castration-Resistant Prostate Cancer
- Abiraterone Acetate
- +2 more
-
Los Angeles, California
- +6 more
Jan 18, 2023
Prostatic Tumors Trial in Worldwide (Radiotherapy, LHRHa, Apalutamide)
Recruiting
- Prostatic Neoplasms
- Radiotherapy
- +2 more
-
Tucson, Arizona
- +145 more
Jan 17, 2023
Treatment Satisfaction With Ra-223 in Japan
Active, not recruiting
- Prostatic Neoplasms
- Radium-223 dichloride (Xofigo, BAY88-8223)
-
Multiple Locations, JapanMany Locations
Jan 12, 2023
Combined mpMRI and PSMA PET/CT for Highly Suspicious Patients
Not yet recruiting
- Prostatic Neoplasms
- +2 more
- (no location specified)
Jan 9, 2023
Prostatic Tumors Trial in Worldwide (Darolutamide (Nubeqa, BAY1841788), Placebo, Androgen deprivation therapy (ADT))
Active, not recruiting
- Prostatic Neoplasms
- Darolutamide (Nubeqa, BAY1841788)
- +2 more
-
Macquarie University, New South Wales, Australia
- +131 more
Jan 5, 2023
Prostatic Tumors, Exercise, Castration-resistant Prostate Cancer Trial in Ghent (Exercise)
Completed
- Prostatic Neoplasms
- +3 more
- Exercise
-
Ghent, Oost-Vlaanderen, BelgiumUniversity Hospital ghent
Dec 22, 2022
Fasting, Prostatic Tumors Trial in Berlin (Fasting, Control)
Completed
- Fasting
- Prostatic Neoplasms
- Fasting
- Control
-
Berlin, GermanyCharité Centrum Chirurgische Medizin, CC 8 Klinik für Urologie
Dec 12, 2022
Prostatic Tumors, Castration-Resistant Trial (64Cu-SAR-BBN, 67Cu-SAR-BBN)
Not yet recruiting
- Prostatic Neoplasms
- Castration-Resistant
- (no location specified)
Dec 1, 2022
Prostatic Tumors Trial in Worldwide (Pembrolizumab, Docetaxel, Prednisone)
Active, not recruiting
- Prostatic Neoplasms
- Pembrolizumab
- +4 more
-
Mobile, Alabama
- +214 more
Nov 24, 2022
Prostatic Tumors Trial in Worldwide (Pembrolizumab, Enzalutamide, Placebo)
Active, not recruiting
- Prostatic Neoplasms
- Pembrolizumab
- +2 more
-
Mobile, Alabama
- +257 more
Nov 22, 2022
Prostatic Tumors, Castration-Resistant, Tumors by Histologic Type, Tumors, Prostate Trial in United States (P-PSMA-101 CAR-T
Active, not recruiting
- Prostatic Neoplasms, Castration-Resistant
- +16 more
- P-PSMA-101 CAR-T cells
- Rimiducid
-
Duarte, California
- +9 more
Nov 15, 2022
Prostate Cancer, Prostate Adenocarcinoma, Prostatic Tumors Trial in Montreal (131I-PSMA-1095 Radioligand Therapy (RLT))
Active, not recruiting
- Prostate Cancer
- +5 more
- 131I-PSMA-1095 Radioligand Therapy (RLT)
-
Montreal, Quebec, CanadaStephan Probst
Oct 24, 2022
Prostatic Tumors Trial in Worldwide (Pembrolizumab, Olaparib, Abiraterone acetate)
Active, not recruiting
- Prostatic Neoplasms
- Pembrolizumab
- +4 more
-
Fullerton, California
- +192 more
Oct 17, 2022
Prostate Cancer, Adenocarcinoma, Prostatic Tumors Trial (bpMRI, Image-Fusion targeted and systematic Biopsy)
Not yet recruiting
- Prostate Cancer
- +4 more
- bpMRI
- Image-Fusion targeted and systematic Biopsy
- (no location specified)
Oct 7, 2022
Prostatic Tumors, Self-Management Trial in Keelung, Taoyuan (Self-management program, Information package)
Recruiting
- Prostatic Neoplasms
- Self-Management
- Self-management program
- Information package
-
Keelung, Taiwan
- +1 more
Sep 27, 2022
Prostatic Tumors Trial in Bronx (Abiraterone Acetate, Prednisone)
Active, not recruiting
- Prostatic Neoplasms
- Abiraterone Acetate
- Prednisone
-
Bronx, New YorkMontefiore Medical Center
Sep 22, 2022
Prostatic Tumors Trial in New York, Myrtle Beach, Houston (ORIC-101, enzalutamide 40 MG oral capsule [Xtandi])
Active, not recruiting
- Prostatic Neoplasms
- ORIC-101
- enzalutamide 40 MG oral capsule [Xtandi]
-
New York, New York
- +2 more
Sep 22, 2022
Prostatic Tumors Trial in San Francisco (Pembrolizumab, SD-101, Leuprolide acetate)
Active, not recruiting
- Prostatic Neoplasms
- Pembrolizumab
- +5 more
-
San Francisco, CaliforniaUniversity of California San Francisco
Sep 20, 2022
Prostate Cancer Among Those WithPositive Family History
Completed
- Prostate Cancer
- +2 more
-
Nasiriyah, Thi Qar, IraqAl-Dar medical Center
Aug 17, 2022